BCL2L11 and non-small cell lung carcinoma: Lee et al. reported that after EGFR TKI treatment, progression-free survival (PFS)is significantly shorter in NSCLC patients harboring the BIM deletion polymorphism than EGFR mutant NSCLC patients with wild-type BIM (11.9 months) [18].